Loading
A phase 2/3 trial of Gemcitabine and Camrelizumab in pancreatic ductal adenocarcinoma, run by Hutchmed, now recruiting.
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer is a phase 2/3 interventional study registered as NCT06361888 by Hutchmed, with 502 participants planned, started 2024-05-08 and due to reach its primary completion in 2028-05-31. Interventions recorded: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine and Surufatinib with Nab-paclitaxel, and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/